Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Anticancer drug targets: cell cycle and checkpoint control
Geoffrey I. Shapiro, J. Wade Harper
Geoffrey I. Shapiro, J. Wade Harper
Published December 15, 1999
Citation Information: J Clin Invest. 1999;104(12):1645-1653. https://doi.org/10.1172/JCI9054.
View: Text | PDF
Perspective

Anticancer drug targets: cell cycle and checkpoint control

  • Text
  • PDF
Abstract

Authors

Geoffrey I. Shapiro, J. Wade Harper

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Cell cycle arrest at G1/S, mediated by cdk inhibitors. Cyclin D–dependen...
Cell cycle arrest at G1/S, mediated by cdk inhibitors. Cyclin D–dependent kinases, assembled with a Cip/Kip protein, and cyclin E–cdk2 complexes are principal holoenzymes that phosphorylate Rb, allowing E2F activation and S phase entry. The induction of INK4 proteins (by TGF-β or during senescence) and their association with cdks 4 and 6 result in decreased affinity for cyclin D, which is ultimately degraded. Displaced Cip/Kip proteins, now free to complex with cyclin E-cdk2, promote cdk2 inhibition and G1 arrest. Replacement of p16INK4A in a tumor cell lacking it only leads to G1 arrest in cells expressing Rb. Antiproliferative signals, including serum starvation, differentiation signals, or DNA damage (which stabilizes p53, resulting in transcriptional induction of p21Waf1/Cip1) can induce high levels of Cip/Kip proteins, which also cause cdk2 inhibition. Ectopic expression of Cip/Kip proteins causes G1 arrest independent of Rb.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts